drugset / Trial / NCT01349816

PT003 MDI Dose Confirmation Study

NCT01349816

Phase 2 Completed 185 enrolled Pearl Therapeutics, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The primary objective of this study is to demonstrate efficacy of PT003 MDI relative to its individual components (PT001 MDI and PT005 MDI) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Timeline

Start
2011-06
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 7.2 ug Inhaled
Subject Formoterol Other / unclassified 9.6 ug Inhaled
Subject Glycopyrrolate Small molecule 9 ug Inhaled
Subject Glycopyrrolate Small molecule 18 ug Inhaled
Subject Glycopyrrolate Small molecule 36 ug Inhaled